Genzyme | Pharma Marketer

Genetix raises $35M to advance gene therapies

Friday, March 12th, 2010

Cambridge, MA-based Genetix Pharmaceuticals has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital.

Posted in: Pharma News | 0 Comments »

Read the full story

PTC’s lead drug ataluren flunks PhIIb

Wednesday, March 3rd, 2010

PTC Therapeutics’ lead drug ataluren failed a Phase IIb trial, flunking a test of its ability to improve the physical performance of patients with a rare genetic disorder. Genzyme is partnered on the program.

Posted in: Pharma News | 0 Comments »

Read the full story

Icahn says he’s ready to ‘fix’ Genzyme

Wednesday, February 24th, 2010

Carl Icahn wasted no time before sliding on the brass knuckles in preparation for his

Posted in: Pharma News | 0 Comments »

Read the full story

Genzyme insiders predict showdown between Termeer, Icahn

Tuesday, February 23rd, 2010

Genzyme CEO Henri Termeer has never made a secret of the high regard he holds for himself. So when the Wall Street Journal noted Termeer’s publicly obliging openness to Carl Icahn’s notice yesterday that he was nominating four people to Genzyme’s board, the business newspaper of record was careful to note that Termeer has often said he was the best person to helm the company. The 25-year Genzyme veteran is credited with taking a fledgling biotech and putting it in the industry’s top tier

Posted in: Pharma News | 0 Comments »

Read the full story

Where Would You Start a Company?

Wednesday, February 10th, 2010

We’ve been talking a lot around here about small companies versus large ones, the merits of different therapeutic areas, and so on. So here’s a question: if you were starting a small drug company today, where would you concentrate its efforts

Posted in: In the Pipeline | 0 Comments »

Read the full story

Isis hits Ph3 endpoint but shares slide on liver worries

Wednesday, February 10th, 2010

Researchers for Genzyme (GENZ) and Isis Pharmaceuticals (ISIS) trumpeted the success of their cholesterol drug mipomersen

Posted in: Pharma News | 0 Comments »

Read the full story

Genzyme gets creative with its exec compensation program

Thursday, January 28th, 2010

With its top executives under the gun for months following some severe problems on the manufacturing side , Genzyme is coming up with a new compensation

Posted in: Pharma News | 0 Comments »

Read the full story

Genzyme CEO makes his case, but Icahn looms

Wednesday, January 13th, 2010

At the J.P. Morgan conference yesterday, Genzyme CEO Henri Termeer ( photo ) took responsibility for the company’s manufacturing missteps over the past year, but assured attendees that he’s still the best person to lead the company out of these tough times.

Posted in: Pharma News | 0 Comments »

Read the full story